as 07-08-2024 4:00pm EST
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.
Founded: | 2010 | Country: | British Virgin Islands |
Employees: | N/A | City: | N/A |
Market Cap: | 8.6M | IPO Year: | 2020 |
Target Price: | N/A | AVG Volume (30 days): | 50.9K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.27 | EPS Growth: | N/A |
52 Week Low/High: | $0.27 - $4.45 | Next Earning Date: | 07-16-2024 |
Revenue: | $2,345,304 | Revenue Growth: | -4.44% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
FRES Breaking Stock News: Dive into FRES Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
GlobeNewswire
a month ago
GlobeNewswire
3 months ago
GlobeNewswire
5 months ago
GlobeNewswire
5 months ago
GlobeNewswire
5 months ago
Simply Wall St.
6 months ago
ACCESSWIRE
6 months ago
The information presented on this page, "FRES Fresh2 Group Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.